Bristol Myers Squibb (BMY) has shown significant improvement in its stock performance, emerging from a period of underperformance. The company recently received FDA approval for an oral schizophrenia drug, marking the first approval of its kind in 70 years. This new drug is set to launch in October. Additionally, BMY has been performing well in the stock market, demonstrating a clean bullish breakout and regaining its daily moving averages. Alongside BMY, Medtronic (MDT) is also performing well in a down tape.